Found: 119
Select item for more details and to access through your institution.
Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2653, doi. 10.1007/s13555-024-01243-8
- By:
- Publication type:
- Article
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2621, doi. 10.1007/s13555-024-01242-9
- By:
- Publication type:
- Article
Patient-reported burden in adults with atopic dermatitis: an international qualitative study.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03130-w
- By:
- Publication type:
- Article
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
- By:
- Publication type:
- Article
Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 6, p. 746, doi. 10.1111/ijd.15853
- By:
- Publication type:
- Article
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 2, p. 139, doi. 10.1111/ijd.15605
- By:
- Publication type:
- Article
Could it be gluten? Additional skin conditions associated with celiac disease.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 1, p. 33, doi. 10.1111/ijd.15750
- By:
- Publication type:
- Article
Real‐world experience of dupilumab in the treatment of moderate‐to‐severe atopic dermatitis.
- Published in:
- International Journal of Dermatology, 2020, v. 59, n. 10, p. e361, doi. 10.1111/ijd.15053
- By:
- Publication type:
- Article
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies.
- Published in:
- Allergy, 2024, v. 79, n. 1, p. 174, doi. 10.1111/all.15952
- By:
- Publication type:
- Article
Proceeding report of the Symposium on Hidradenitis Suppurativa Advances ( SHSA).
- Published in:
- Experimental Dermatology, 2018, v. 27, n. 1, p. 104, doi. 10.1111/exd.13445
- By:
- Publication type:
- Article
Predictors of Topical Use in Psoriasis Patients in the REFINE Study.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2016, v. 20, n. 2, p. 106, doi. 10.1177/1203475415604322
- By:
- Publication type:
- Article
Real-World Experience with Alitretinoin in a Community Dermatology Practice Setting in Patients with Chronic Hand Dermatitis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2014, v. 18, n. 5, p. 332, doi. 10.2310/7750.2014.13195
- By:
- Publication type:
- Article
New Topical Therapies in Development for Atopic Dermatitis.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 843, doi. 10.1007/s40265-022-01722-2
- By:
- Publication type:
- Article
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2285, doi. 10.1007/s13555-024-01200-5
- By:
- Publication type:
- Article
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1211, doi. 10.1007/s13555-024-01155-7
- By:
- Publication type:
- Article
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1145, doi. 10.1007/s13555-024-01158-4
- By:
- Publication type:
- Article
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 1007, doi. 10.1007/s13555-024-01147-7
- By:
- Publication type:
- Article
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 2, p. 441, doi. 10.1007/s13555-023-01075-y
- By:
- Publication type:
- Article
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 1893, doi. 10.1007/s13555-023-00948-6
- By:
- Publication type:
- Article
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 4, p. 867, doi. 10.1007/s13555-023-00905-3
- By:
- Publication type:
- Article
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 535, doi. 10.1007/s13555-022-00870-3
- By:
- Publication type:
- Article
Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 235, doi. 10.1007/s13555-022-00853-4
- By:
- Publication type:
- Article
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 269, doi. 10.1007/s13555-022-00849-0
- By:
- Publication type:
- Article
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 11, p. 2499, doi. 10.1007/s13555-022-00805-y
- By:
- Publication type:
- Article
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2077, doi. 10.1007/s13555-022-00764-4
- By:
- Publication type:
- Article
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 6, p. 1431, doi. 10.1007/s13555-022-00743-9
- By:
- Publication type:
- Article
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 5, p. 1073, doi. 10.1007/s13555-022-00722-0
- By:
- Publication type:
- Article
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 727, doi. 10.1007/s13555-022-00690-5
- By:
- Publication type:
- Article
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
- By:
- Publication type:
- Article
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 253, doi. 10.1007/s13555-021-00642-5
- By:
- Publication type:
- Article
Practical Management of Patients with Atopic Dermatitis on Dupilumab.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1805, doi. 10.1007/s13555-021-00586-w
- By:
- Publication type:
- Article
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 4, p. 1107, doi. 10.1007/s13555-021-00548-2
- By:
- Publication type:
- Article
Psoriasis Prevalence and Severity by Expert Elicitation.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 3, p. 1053, doi. 10.1007/s13555-021-00518-8
- By:
- Publication type:
- Article
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 3, p. 431, doi. 10.1007/s13555-020-00367-x
- By:
- Publication type:
- Article
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
- Published in:
- Dermatology & Therapy, 2020, v. 10, n. 1, p. 133, doi. 10.1007/s13555-019-00340-3
- By:
- Publication type:
- Article
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.
- Published in:
- Journal of Clinical & Aesthetic Dermatology, 2023, v. 16, n. 9, p. 42
- By:
- Publication type:
- Article
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
- Published in:
- BMC Dermatology, 2016, v. 16, p. 1, doi. 10.1186/s12895-016-0051-4
- By:
- Publication type:
- Article
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials.
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 753, doi. 10.1002/jvc2.203
- By:
- Publication type:
- Article
Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q).
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 2, p. 282, doi. 10.1002/jvc2.126
- By:
- Publication type:
- Article
Return of Lymantria dispar dispar (gypsy moth): A case report.
- Published in:
- SAGE Open Medical Case Reports, 2021, v. 9, p. 1, doi. 10.1177/2050313X211057926
- By:
- Publication type:
- Article
Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report.
- Published in:
- SAGE Open Medical Case Reports, 2021, v. 9, p. 1, doi. 10.1177/2050313X211039477
- By:
- Publication type:
- Article
A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors.
- Published in:
- SAGE Open Medical Case Reports, 2021, v. 9, p. 1, doi. 10.1177/2050313X211034925
- By:
- Publication type:
- Article
Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report.
- Published in:
- SAGE Open Medical Case Reports, 2019, v. 7, p. N.PAG, doi. 10.1177/2050313X19829620
- By:
- Publication type:
- Article
Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report.
- Published in:
- SAGE Open Medical Case Reports, 2019, v. 7, p. N.PAG, doi. 10.1177/2050313X19829620
- By:
- Publication type:
- Article
Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections.
- Published in:
- SAGE Open Medical Case Reports, 2018, v. 6, p. 1, doi. 10.1177/2050313X18778723
- By:
- Publication type:
- Article
Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 10, p. 1, doi. 10.1111/dth.15777
- By:
- Publication type:
- Article